EU moves to back critical medicines production as chemicals trade policy may follow
The EU is advancing a Critical Medicines Act to support domestic output of key drugs and ingredients, while similar protectionist rules for chemicals are being discussed but are less advanced.
Key Facts
- The European Parliament and member-state ministers agreed the Critical Medicines Act in May.
- The act is intended to incentivize EU-based manufacturing of critical medicines and their active ingredients.
- The report said many generic drugs are now made mainly outside Europe, especially in China and India.
- Swiss drugmaker Sandoz asked the European Commission to investigate imports of amoxicillin trihydrate from China.
- A commission spokesperson said final adoption of the act is likely in autumn 2026 after legal checks.
What Happened
The EU is moving closer to strengthening stockpiles and domestic production of key medicines through its Critical Medicines Act. The rules were agreed by the European Parliament and ministers from member states in May, and the report said adoption is likely in autumn 2026 after legal checks.
The same report said lawmakers are also considering similar rules for chemicals and other sectors, but those ideas are not yet as advanced. The policy direction is framed around reducing dependence on supply chains tied to China.
Why It Matters
For buyers and operators, the significance is not just policy signaling. The report said the EU wants to incentivize EU-based manufacturing of critical medicines and active ingredients, which could reshape sourcing, availability, and pricing in downstream supply chains.
That matters because many generic drugs are now made mainly outside Europe, especially in China and India, with upstream precursors and ingredients often coming from China even when finished medicines are exported from India. The report also said Sandoz has complained about alleged economic dumping of amoxicillin trihydrate from China.
Key Details
The article pointed to several practical markers of where EU policy is heading and why supply-chain risk is being discussed more openly.
- The Critical Medicines Act is meant to incentivize EU production of critical medicines and their active ingredients.
- Possible chemicals-sector rules are being discussed, but they are less advanced than the medicines proposal.
- Sandoz called on the European Commission to investigate imports of amoxicillin trihydrate from China.
- Stefano Riela of Bocconi University said the EU faces dependence on suppliers that cannot be considered politically close.
For chemical buyers, the clearest near-term signal is that Brussels is increasingly treating upstream concentration as a strategic issue, not just a market one. That can affect procurement strategies where ingredients or intermediates sit inside highly concentrated global networks.
What To Watch Next
Watch for the final EU adoption process on the medicines act, including legal checks and any autumn 2026 timing. Also watch whether the chemicals discussion moves from rumor and positioning into a formal policy proposal.
If similar measures emerge for chemicals, companies tied to Chinese-origin intermediates, active ingredients, or closely linked upstream inputs may face more scrutiny, more compliance questions, and potentially more pressure to diversify supply.
Alliance's Take
Buyers should review exposure to Chinese-origin intermediates and active ingredients now, especially where a single upstream source supports multiple finished products.
For compliance and operations teams, this is a prompt to map critical supply lines, confirm alternate sources, and prepare for tighter origin and resilience expectations if chemicals policy follows medicines policy.
Related Products
Frequently Asked Questions
What is the EU trying to change with the Critical Medicines Act?
The act is meant to incentivize EU-based manufacturing of critical medicines and their active ingredients, reducing reliance on external supply.
Why is China central to this policy discussion?
The report said many generic drugs and upstream ingredients are made mainly outside Europe, with China seen as a major supply risk and source of concentrated upstream production.
Could chemicals face similar EU rules?
The report said similar rules for chemicals and other sectors are being discussed, but they are not yet as advanced as the medicines proposal.
Sources
- EU looks to boost protective trade policy against Chinese imports — Chemistry World (2026)
- Publishing
